ZA96448B - Tablet - Google Patents

Tablet

Info

Publication number
ZA96448B
ZA96448B ZA96448A ZA96448A ZA96448B ZA 96448 B ZA96448 B ZA 96448B ZA 96448 A ZA96448 A ZA 96448A ZA 96448 A ZA96448 A ZA 96448A ZA 96448 B ZA96448 B ZA 96448B
Authority
ZA
South Africa
Prior art keywords
tablet
Prior art date
Application number
ZA96448A
Other languages
English (en)
Inventor
Barry Howard Carter
Lloyd Gary Tillman
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA96448(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ZA96448B publication Critical patent/ZA96448B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA96448A 1995-01-20 1996-01-19 Tablet ZA96448B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501127.6A GB9501127D0 (en) 1995-01-20 1995-01-20 Tablet

Publications (1)

Publication Number Publication Date
ZA96448B true ZA96448B (en) 1996-08-07

Family

ID=10768317

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA96448A ZA96448B (en) 1995-01-20 1996-01-19 Tablet

Country Status (38)

Country Link
US (1) US5879706A (en:Method)
EP (1) EP0806943B1 (en:Method)
JP (1) JP3350055B2 (en:Method)
KR (1) KR100412298B1 (en:Method)
CN (2) CN1313081C (en:Method)
AP (1) AP666A (en:Method)
AT (1) ATE190483T1 (en:Method)
AU (1) AU710823B2 (en:Method)
BG (1) BG63187B1 (en:Method)
BR (1) BR9606769A (en:Method)
CA (1) CA2210891C (en:Method)
CY (1) CY2182B1 (en:Method)
CZ (1) CZ296514B6 (en:Method)
DE (1) DE69607146T2 (en:Method)
DK (1) DK0806943T3 (en:Method)
EA (1) EA000276B1 (en:Method)
EE (1) EE03336B1 (en:Method)
ES (1) ES2145425T3 (en:Method)
FI (1) FI119722B (en:Method)
GB (1) GB9501127D0 (en:Method)
GE (1) GEP20022752B (en:Method)
GR (1) GR3033677T3 (en:Method)
HU (1) HU226131B1 (en:Method)
IL (1) IL116830A (en:Method)
IN (1) IN181318B (en:Method)
MY (1) MY126346A (en:Method)
NO (1) NO311488B1 (en:Method)
NZ (1) NZ298846A (en:Method)
OA (1) OA10500A (en:Method)
PL (1) PL185307B1 (en:Method)
PT (1) PT806943E (en:Method)
RO (1) RO118175B1 (en:Method)
SK (1) SK282030B6 (en:Method)
TR (1) TR199700657T1 (en:Method)
UA (1) UA68325C2 (en:Method)
UY (2) UY25774A1 (en:Method)
WO (1) WO1996022082A1 (en:Method)
ZA (1) ZA96448B (en:Method)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
ATE254463T1 (de) * 1996-01-19 2003-12-15 Glaxo Group Ltd Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AU2478900A (en) * 1998-12-18 2000-07-12 Abbott Laboratories Controlled release formulation of divalproex sodium
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
AU2002236166B2 (en) * 2001-05-01 2006-12-07 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
CA2465420A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
KR20070020149A (ko) * 2001-11-14 2007-02-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르의 합성 및 정제 방법
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
KR100871621B1 (ko) * 2003-06-02 2008-12-02 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르 히드로클로라이드의 신규한 결정질 형태
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
CA2536487C (en) 2003-09-12 2011-10-25 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
ATE301455T1 (de) * 2003-12-09 2005-08-15 Helm Ag Pharmazeutische zubereitung enthaltend valaciclovir
US7344907B2 (en) * 2004-11-19 2008-03-18 International Business Machines Corporation Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
KR101116747B1 (ko) 2004-12-06 2012-02-22 에스케이케미칼주식회사 안정성이 개선된 말레인산 암로디핀 약제 조성물
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
ATE546451T1 (de) * 2005-05-25 2012-03-15 Lilly Co Eli Cyclopropancarbonsäureester von acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
US20090312439A1 (en) * 2006-05-10 2009-12-17 Ralph Hofmann Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
DK2037887T3 (da) * 2006-05-31 2011-01-03 Vertex Pharma Orale formuleringer med kontrolleret frigørelse af en interleukin-1 beta-konverteringsenzyminhibitor
EP2040684B1 (en) * 2006-07-11 2013-01-23 LEK Pharmaceuticals d.d. Multiple unit tablets
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
DK2407166T3 (da) * 2009-03-13 2013-10-07 Toyama Chemical Co Ltd Tablet og granuleret pulver indeholdende 6-fluor-3-hydroxy-2-pyrazin-carboxamid
CH703348A1 (de) * 2010-06-29 2011-12-30 Mepha Gmbh Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen.
GB2515486A (en) * 2013-06-24 2014-12-31 Kraft Foods R & D Inc Soluble Beverage Ingredients
KR101497508B1 (ko) * 2013-12-20 2015-03-03 한국유나이티드제약 주식회사 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN110279667B (zh) * 2019-07-30 2023-02-10 珠海润都制药股份有限公司 一种盐酸伐昔洛韦片及其制备方法
US20230201234A1 (en) * 2020-06-01 2023-06-29 Shilpa Medicare Ltd Fast dispersible pharmaceutical composition comprising capecitabine
TWI884340B (zh) * 2020-12-01 2025-05-21 南韓商Ｌｇ化學股份有限公司 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法
CN119789849A (zh) * 2022-08-31 2025-04-08 阿斯利康(瑞典)有限公司 药物制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
DE68903605T2 (de) * 1988-05-04 1993-04-01 Smith Kline French Lab Kautablette.
DE4290300T1 (de) * 1991-01-30 1993-10-07 Wellcome Found Wasserdispergierbare Tabletten
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet

Also Published As

Publication number Publication date
EP0806943B1 (en) 2000-03-15
EA199700123A1 (ru) 1997-12-30
IL116830A0 (en) 1996-05-14
NO311488B1 (no) 2001-12-03
DK0806943T3 (da) 2000-07-24
US5879706A (en) 1999-03-09
CN1313081C (zh) 2007-05-02
FI973062L (fi) 1997-09-18
SK96497A3 (en) 1998-01-14
GEP20022752B (en) 2002-08-26
BG63187B1 (bg) 2001-06-29
AU4453496A (en) 1996-08-07
JPH10512564A (ja) 1998-12-02
CN1494898A (zh) 2004-05-12
CA2210891A1 (en) 1996-07-25
CN1131026C (zh) 2003-12-17
DE69607146D1 (de) 2000-04-20
HUP9801872A2 (hu) 1999-10-28
KR19980701524A (ko) 1998-05-15
ES2145425T3 (es) 2000-07-01
EE03336B1 (et) 2001-02-15
HK1002851A1 (en) 1998-09-25
CN1179100A (zh) 1998-04-15
PT806943E (pt) 2000-08-31
EP0806943A1 (en) 1997-11-19
MY126346A (en) 2006-09-29
BR9606769A (pt) 1997-12-30
NZ298846A (en) 1998-06-26
NO973327L (no) 1997-09-16
ATE190483T1 (de) 2000-04-15
OA10500A (en) 2002-04-10
AP666A (en) 1998-08-24
NO973327D0 (no) 1997-07-18
TR199700657T1 (xx) 1998-02-21
HU226131B1 (en) 2008-05-28
UA68325C2 (en) 2004-08-16
BG101831A (en) 1998-04-30
PL321361A1 (en) 1997-12-08
CY2182B1 (en) 2002-08-23
IN181318B (en:Method) 1998-05-09
GR3033677T3 (en) 2000-10-31
CA2210891C (en) 2009-05-19
AP9701057A0 (en) 1997-10-31
UY25774A1 (es) 2000-10-31
GB9501127D0 (en) 1995-03-08
DE69607146T2 (de) 2000-09-21
CZ229297A3 (cs) 1998-02-18
EA000276B1 (ru) 1999-02-25
FI973062A0 (fi) 1997-07-18
JP3350055B2 (ja) 2002-11-25
SK282030B6 (sk) 2001-10-08
AU710823B2 (en) 1999-09-30
KR100412298B1 (ko) 2004-04-21
HUP9801872A3 (en) 2001-02-28
WO1996022082A1 (en) 1996-07-25
IL116830A (en) 2000-02-29
RO118175B1 (ro) 2003-03-28
CZ296514B6 (cs) 2006-03-15
UY25778A1 (es) 2000-08-21
FI119722B (fi) 2009-02-27
MX9705459A (es) 1997-10-31
PL185307B1 (pl) 2003-04-30

Similar Documents

Publication Publication Date Title
ZA96448B (en) Tablet
IL123614A0 (en) Chewable tablet
AU132520S (en) Tablet
AU128017S (en) Pharmaceutical tablet
DE69610843D1 (en) Hydroformylierungsverfahren
AU129056S (en) Pharmaceutical tablet
AU133610S (en) Tablet
EP0852208A4 (en) TABLET CONTAINER
GB9518465D0 (en) Pharmaceuticals
GB9509388D0 (en) Hsbwls
AP9600802A0 (en) Libricant
CA77348S (en) Tablet
GB9525706D0 (en) Tablet dispencer
CA76097S (en) Can
AU1105P (en) DALESE Metrosideros excelsus
GB9511993D0 (en) Pharmaceuticals
GB9506170D0 (en) Pharmaceuticals
GB9513768D0 (en) Pharmaceuticals
GB9513207D0 (en) Pharmaceuticals
GB9513208D0 (en) Pharmaceuticals
GB9517038D0 (en) Pharmaceuticals
GB9513210D0 (en) Pharmaceuticals
GB9508237D0 (en) Pharmaceuticals
GB9526703D0 (en) Pharmaceuticals
GB9507708D0 (en) Pharmaceuticals